Upon injection into an aqueous environment (e.g. a tumor), the ISFI will phase invert from a liquid solution into a solid depot, co-releasing a chemotherapeutic, Doxorubicin (Dox), and a Pgp inhibitor, P85 or Val. Here, PGP is linked to neoplasm.